Skip to main content

$119M Opioid Crisis Settlement Announced By Idaho

$119M Opioid Crisis Settlement Announced By Idaho

$119M Opioid Crisis Settlement Announced By Idaho

Introduction

Johnson & Johnson (J&J) and three major drug distributors have reached a $119 million settlement with the Idaho officials over the companies' role in the opioid crisis.

It is the second-largest consumer settlement in state history after the national tobacco settlement of $712 million in 1998. The state became eligible for a minimum of $64 million settlement, but the participation of the local government entities has resulted in boosting the amount to $119 million.

The attorneys representing the state said that Idaho had implemented several ways to deal with the opioid crisis throughout the past few years, and the current settlement would offer additional resources to combat the crisis.

As per the agreement, J&J would pay $21 million over nine years, whereas the drug distributors are required to pay $98 million over 18 years. The settlement amount would be a huge asset to the state for funding treatment, recovery, and prevention programmes in Idaho.

The agreement even states the breakup of the amount by allocating 40% of the money to the participating counties and cities, 20% to regional public health districts, and the remaining 40% would go to the state-directed opioid settlement fund.

Apart from settlement, the agreement even provided guidelines on the sale and distribution of opioids. The agreement even calls for an independent monitoring process that will stop the deliveries of opioids in case of misuse occurring. J&J is banned from selling and promoting opioids as per the agreement.

In February, J&J, along with the three drug distributors, reached a $26 billion national opioid settlement to deal with the nationwide crisis. In 2017, the federal government declared a public health emergency, and the settlement will address the damage caused because of the crisis.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Supreme Court Upholds Flavored Vape Ban

Categories: E-Cigarette: JUUL

The U.S. Supreme Court has unanimously upheld a decision by the Food and Drug Administration (FDA) to block the sale and marketing of certain flavored e-cigarette products.

The ruling supports the FDA’s authority to regulate tobacco…

Judge Rejects JnJ's $10B Talc Lawsuit Settlement

Categories: Talcum

Johnson & Johnson's shares fell more than 5% after a U.S. bankruptcy judge rejected its $10 billion settlement proposal aimed at resolving over 60,000 lawsuits. 

These lawsuits allege that the company’s…

Tepezza Hearing Loss MDL: Bellwether Trials Set for 2026

Categories: Tepezza

A U.S. District Judge overseeing Tepezza hearing damage lawsuits nationwide has scheduled four bellwether trials for 2026. These trials are intended to help both parties assess how juries may respond to the evidence and testimonies that could be…

🛠️ You Have Unfinished Work. We’ll Finish It — Free Trial.            
Free Trial + 25% Off All DLs & Med Review Case Backlog!

Only 12 Firms Can Join – First Come, First Served